12:54 PM EST, 01/07/2025 (MT Newswires) -- Verona Pharma ( VRNA ) on Tuesday said it expects Q4 net product sales of $36 million on the back of the commercial launch of Ohtuvayre, a treatment for chronic obstructive pulmonary disease, a lung condition.

Full-year 2024 net product sales are expected to be $42 million, the company said.

Meanwhile, the company said it expected to report $400 million in cash and cash equivalents as of Dec. 31, 2024.

Price: 48.95, Change: +4.14, Percent Change: +9.24